Breast chemotherapy response assay
This article was originally published in The Gray Sheet
Executive Summary
Genomic Health's Oncotype Dx breast cancer recurrence assay stratifies chemotherapy benefit in 651 patients studied by the National Surgical Adjuvant Breast & Bowel Project, the Redwood City, Calif. firm announces with NSABP at the San Antonio Breast Cancer Symposium Dec. 10. The National Cancer Institute-supported trial showed that high recurrence scores - associated with 25% of patients with "node-negative, estrogen receptor-positive breast cancer" - determine "a large absolute benefit from chemotherapy." Low recurrence scores were linked with minimal benefit and represented about 50% of such patients. Unveiling of the data coincided with early release of an article to be published in the New England Journal of Medicine Dec. 30. The NEJM study is a large validation trial confirming that the 21-gene panel predicts breast cancer recurrence in tamoxifen-treated, node-negative patients. Oncotype Dx was approved under the Clinical Laboratory Improvement Amendments (CLIA) in January...
You may also be interested in...
Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV
Exagen Diagnostics is working with FDA to design a pivotal trial assessing whether results from an earlier study of the firm's breast cancer recurrence genomic test can be duplicated in a larger cohort
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.